Last 12 months
Inside the activity.
0 purchase rows · 57 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 16 |
| Dec 2025 | 0 | 12 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 9 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 15, 2019 Filed Nov 18, 2019 21:19 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001384101-19-000136 · wf-form4_157411197089300.xml · derivative · entry 4 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,241 Underlying: Common Stock · 20,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:19 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
SaleCommon Stock | 20,000 | $25.06 | $501,124.00 |
DisclosureSEC source: 0001384101-19-000136 · wf-form4_157411197089300.xml · nonDerivative · entry 2 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,726 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.00 to $25.22. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:19 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 20,000 | $4.00 | $80,000.00 |
DisclosureSEC source: 0001384101-19-000136 · wf-form4_157411197089300.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 22:42 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 16,091 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000134 · wf-form4_157195688905784.xml · derivative · entry 4 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,909 Underlying: Common Stock · 16,091 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 22:42 UTC |
Hanna John Walter JRChief Commercial Officer
|
SaleCommon Stock | 300 | $28.03 | $8,408.49 |
DisclosureSEC source: 0001384101-19-000134 · wf-form4_157195688905784.xml · nonDerivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.01 to $28.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 22:42 UTC |
Hanna John Walter JRChief Commercial Officer
|
SaleCommon Stock | 15,791 | $27.50 | $434,320.40 |
DisclosureSEC source: 0001384101-19-000134 · wf-form4_157195688905784.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,792 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $27.00 to $27.99. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 22:42 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 16,091 | $6.45 | $103,786.95 |
DisclosureSEC source: 0001384101-19-000134 · wf-form4_157195688905784.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 22:39 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,243 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000133 · wf-form4_157195661921684.xml · derivative · entry 3 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,007 Underlying: Common Stock · 1,243 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F2 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 22:39 UTC |
Kennedy KeithCOO / CFO
|
SaleCommon Stock | 1,243 | $28.00 | $34,804.00 |
DisclosureSEC source: 0001384101-19-000133 · wf-form4_157195661921684.xml · nonDerivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,043 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 22:39 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionCommon Stock | 1,243 | $5.98 | $7,433.14 |
DisclosureSEC source: 0001384101-19-000133 · wf-form4_157195661921684.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 20:25 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,259 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001384101-19-000128 · wf-form4_157082552609526.xml · derivative · entry 6 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,241 Underlying: Common Stock · 2,259 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 20:25 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,041 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001384101-19-000128 · wf-form4_157082552609526.xml · derivative · entry 5 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,041 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 20:25 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
SaleCommon Stock | 8,000 | $24.50 | $196,004.80 |
DisclosureSEC source: 0001384101-19-000128 · wf-form4_157082552609526.xml · nonDerivative · entry 3 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,726 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.28 to $24.85. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 20:25 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 2,259 | $4.00 | $9,036.00 |
DisclosureSEC source: 0001384101-19-000128 · wf-form4_157082552609526.xml · nonDerivative · entry 2 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 20:25 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 5,041 | $2.68 | $13,509.88 |
DisclosureSEC source: 0001384101-19-000128 · wf-form4_157082552609526.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 20:06 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionStock Option (right to buy) · Derivative | 22,365 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001384101-19-000126 · wf-form4_156900999279669.xml · derivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,635 Underlying: Common Stock · 22,365 shares Expires 2026-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option began to vest on December 6, 2017 and vests at a rate of 1/36th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 18, 2019 Filed Sep 20, 2019 20:06 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionCommon Stock | 22,365 | $7.47 | $167,066.55 |
DisclosureSEC source: 0001384101-19-000126 · wf-form4_156900999279669.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:50 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 18,593 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000124 · wf-form4_156875340783665.xml · derivative · entry 3 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,907 Underlying: Common Stock · 18,593 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:50 UTC |
Hanna John Walter JRChief Commercial Officer
|
SaleCommon Stock | 18,593 | $25.66 | $477,088.94 |
DisclosureSEC source: 0001384101-19-000124 · wf-form4_156875340783665.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.21 to $26.04. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 20:50 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionCommon Stock | 18,593 | $5.98 | $111,186.14 |
DisclosureSEC source: 0001384101-19-000124 · wf-form4_156875340783665.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 21:45 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
SaleCommon Stock | 4,815 | $25.04 | $120,560.38 |
DisclosureSEC source: 0001384101-19-000122 · wf-form4_156832469879109.xml · nonDerivative · entry 3 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,426 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.80 to $25.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 21:45 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
SaleCommon Stock | 1,787 | $24.08 | $43,025.96 |
DisclosureSEC source: 0001384101-19-000122 · wf-form4_156832469879109.xml · nonDerivative · entry 2 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,241 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $23.72 to $24.71. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 21:45 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
SaleCommon Stock | 1,398 | $23.27 | $32,527.69 |
DisclosureSEC source: 0001384101-19-000122 · wf-form4_156832469879109.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,028 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $22.69 to $23.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 04, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 296 | $25.20 | $7,457.99 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,449 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:25 UTC |
Ho MarkPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 66 | $25.09 | $1,655.94 |
DisclosureSEC source: 0001384101-19-000120 · wf-form4_156771874109666.xml · nonDerivative · entry 1 Ho Mark · CIK 0001554165 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,823 F1 · shares: The reporting person is reporting the withholding of 66 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 188 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. F2 · balance_after: Includes 702 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · derivative · entry 12 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,063 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F8 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,313 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · derivative · entry 11 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,875 Underlying: Common Stock · 5,313 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F7 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,562 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · derivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,648 Underlying: Common Stock · 1,562 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,503 Underlying: Common Stock · 3,750 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Tax withholdingCommon Stock | 292 | $25.09 | $7,326.28 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 F4 · shares: The reporting person is reporting the withholding of 292 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 2,000 | $26.12 | $52,245.00 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.81 to $26.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 13,031 | $25.20 | $328,411.17 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.81 to $25.80. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 4,406 | $5.98 | $26,347.88 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 5,313 | $9.05 | $48,082.65 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 1,562 | $5.43 | $8,481.66 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:23 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 3,750 | $6.45 | $24,187.50 |
DisclosureSEC source: 0001384101-19-000118 · wf-form4_156771858377334.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:21 UTC |
Hanna John Walter JRChief Commercial Officer
|
Tax withholdingCommon Stock | 152 | $25.09 | $3,813.68 |
DisclosureSEC source: 0001384101-19-000116 · wf-form4_156771844700157.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,492 F1 · shares: The reporting person is reporting the withholding of 152 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 438 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. F2 · balance_after: Includes 287 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:16 UTC |
Kennedy KeithCOO / CFO
|
Tax withholdingCommon Stock | 340 | $25.09 | $8,530.60 |
DisclosureSEC source: 0001384101-19-000114 · wf-form4_156771820176780.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,678 F1 · shares: The reporting person is reporting the withholding of 340 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 644 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. F2 · balance_after: Includes 807 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2019. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:14 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 988 | $25.09 | $24,788.92 |
DisclosureSEC source: 0001384101-19-000112 · wf-form4_156771802941012.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,426 F1 · shares: The reporting person is reporting the withholding of 988 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,875 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person. Read SEC document |
| August 28, 2019 Filed Aug 29, 2019 20:32 UTC |
JONES EVAN/ FADirector
|
SaleCommon Stock | 6,600 | $26.10 | $172,290.36 |
DisclosureSEC source: 0001384101-19-000110 · wf-form4_156711072707256.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 179,653 F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.95 to $26.39. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F2 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 27, 2019 Filed Aug 29, 2019 20:32 UTC |
JONES EVAN/ FADirector
|
SaleCommon Stock | 3,400 | $26.11 | $88,760.40 |
DisclosureSEC source: 0001384101-19-000110 · wf-form4_156711072707256.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 186,253 F1 · price: Represents weighted average sales price. Sale prices for the transactions range from $26.00 to $26.25. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F2 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,640 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 16 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 4,640 shares Expires 2024-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 4,640 | $25.45 | $118,088.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,037 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 20:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 4,640 | $10.45 | $48,488.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · nonDerivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 21:08 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,459 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001384101-19-000106 · wf-form4_156573047353478.xml · derivative · entry 4 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,041 Underlying: Common Stock · 1,459 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 21:08 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
SaleCommon Stock | 8,000 | $25.28 | $202,236.80 |
DisclosureSEC source: 0001384101-19-000106 · wf-form4_156573047353478.xml · nonDerivative · entry 2 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,414 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.11 to $25.94. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 21:08 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 1,459 | $2.68 | $3,910.12 |
DisclosureSEC source: 0001384101-19-000106 · wf-form4_156573047353478.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 22, 2018. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,406 | $0.00 Strike: $5.98 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 15 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,469 Underlying: Common Stock · 4,406 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F7 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,083 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 14 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,188 Underlying: Common Stock · 7,083 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:15 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,563 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001384101-19-000108 · wf-form4_156581372426743.xml · derivative · entry 13 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,210 Underlying: Common Stock · 1,563 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.